High levels of PD-L1 have been observed in cisplatin-resistant small-cell lung carcinoma cells and enzalutamide-resistant prostate cancer cells36, suggesting the need for further investigation into the effects of rapamycin and other anticancer drugs on resistant cancer cells. This evidence concerns the gene CD274 and prostate cancer.